Latest news with #CorePlus
Associated Press
5 days ago
- Business
- Associated Press
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Western Asset Management Company, LLC Mutual Fund Investors to Secure Counsel Before Important Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - July 16, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the 'Western Asset US Core Bond Fund' mutual fund classes - Class I (ticker: 'WATFX'), Class A (ticker: 'WABAX'), Class C (ticker: 'WABCX'), Class FI (ticker: 'WAPIX'), Class IS (ticker: 'WACSX'), and Class R (ticker: 'WABRX') - and the 'Western Asset Core Plus Bond Fund' mutual fund classes - Class A (ticker: 'WAPAX'), Class C (ticker: 'WAPCX'), Class C1 (ticker: 'LWCPX'), Class FI (ticker: 'WACIX'), Class R (ticker: 'WAPRX'), Class I (ticker: 'WACPX'), Class IS (ticker: 'WAPSX') between January 1, 2021 and October 31, 2023, inclusive (the 'Class Period'), of the important September 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased WAMCO mutual funds during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the WAMCO class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants failed to warn investors that: (1) defendants favored certain WAMCO strategies, like Macro Opps, over other WAMCO strategies, like Core and Core Plus; (2) defendants disfavored certain WAMCO strategies, like Core and Core Plus; (3) any 'compliance policies and procedures' that WAMCO maintained 'to result in fair allocations of investment opportunities to clients' were either insufficient to ensure that Leech and his WAMCO Team fairly allocated trades among the strategies they managed or were expressly disregarded by defendants in order to allow the favoring of certain WAMCO strategies at the expense of other WAMCO strategies; (3) any 'oversight mechanisms' that WAMCO maintained were either insufficient to monitor Leech and his WAMCO Team or were expressly disregarded by defendants in order to allow the favoring of certain WAMCO strategies at the expense of other WAMCO strategies. As a result, defendants' actions operated as a fraud or deceit on the Class, artificially reducing the price of the 'Western Asset US Core strategy' mutual fund classes during the Class Period, damaging Class members. To join the WAMCO class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Business Wire
08-07-2025
- Business
- Business Wire
Rosen Law Firm Urges Western Asset Management Company, LLC Mutual Fund Investors with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action lawsuit on behalf of purchasers of the 'Western Asset US Core Bond Fund' mutual fund classes – Class I (ticker: 'WATFX'), Class A (ticker: 'WABAX'), Class C (ticker: 'WABCX'), Class FI (ticker: 'WAPIX'), Class IS (ticker: 'WACSX'), and Class R (ticker: 'WABRX') – and the 'Western Asset Core Plus Bond Fund' mutual fund classes – Class A (ticker: 'WAPAX'), Class C (ticker: 'WAPCX'), Class C1 (ticker: 'LWCPX'), Class FI (ticker: 'WACIX'), Class R (ticker: 'WAPRX'), Class I (ticker: 'WACPX'), Class IS (ticker: 'WAPSX') between January 1, 2021 and October 31, 2023, inclusive (the 'Class Period'). Western Asset Management Company, LLC (or, 'WAMCO') offers investment products and investment management and advisory services. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Western Asset Management Company, LLC Misled Investors Regarding its Business Operations. According to the lawsuit, throughout the Class Period, defendants failed to warn investors that: (1) Defendants favored certain WAMCO strategies, like Macro Opps, over other WAMCO strategies, like Core and Core Plus; (2) Defendants disfavored certain WAMCO strategies, like Core and Core Plus; (3) any 'compliance policies and procedures' that WAMCO maintained 'to result in fair allocations of investment opportunities to clients' were either insufficient to ensure that Leech and his WAMCO Team fairly allocated trades among the strategies they managed or were expressly disregarded by defendants in order to allow the favoring of certain WAMCO strategies at the expense of other WAMCO strategies; (3) any 'oversight mechanisms' that WAMCO maintained were either insufficient to monitor Leech and his WAMCO Team or were expressly disregarded by Defendants in order to allow the favoring of certain WAMCO strategies at the expense of other WAMCO strategies. As a result, defendants' actions operated as a fraud or deceit on the Class, artificially reducing the price of the 'Western Asset US Core strategy' mutual fund classes during the Class Period, damaging Class members. What Now: You may be eligible to participate in the class action against Western Asset Management Company. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 5, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
30-05-2025
- Health
- Yahoo
AIxMed and CorePlus Partner to Demonstrate a Digital Urine Cytology Workflow Solution
AIxMed and CorePlus team up to bring AI-driven quality control to improve bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus have entered a Memorandum of Understanding to evaluate a Quality Control workflow solution for urine cytology. The partnership aims to demonstrate the integration of artificial intelligence into the urine cytology workflow, enhancing diagnostic consistency, efficiency, and scalability. AIxMed's experience in AI-based cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only cytology analysis. "We are thrilled to collaborate with CorePlus in demonstrating how AIxURO can seamlessly integrate into their digital pathology workflow. This effort builds on the success of our previous studies and marks an important milestone toward modernizing cytology quality control (QC) through digital and AI tools," said Samuel Chen, CEO of AIxMed. "AIxURO offers significant time savings with consistent results. Integrating our scanner with real-time AI-based QC checks significantly improves efficiency and diagnostic accuracy. Precision cytology is no longer a vision—it's reality," said Mariano de Socarraz, Founder, and CEO of CorePlus. The scarcity of cytologists and the manual process involved in cell characterization necessitate the development of advanced tools to enhance workflow and offer both quantitative and qualitative insights. AI-driven computational tools have the potential to provide these valuable insights and enable the processing of a greater number of slides with the existing workforce. To learn more about these solutions or to request a demonstration, please visit About AIxMedFounded in 2018, AIxMed is creating a roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform. This solution simplifies clinical workflows and richly strengthens the quality of healthcare by aiding critical decision support during clinical diagnosis and monitoring. To learn more visit About CorePlusCorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. To learn more visit View original content to download multimedia: SOURCE AIxMed, Inc.
Malaysian Reserve
28-05-2025
- Health
- Malaysian Reserve
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ — CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. 'We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!' Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. 'Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact.' For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System – Rivera Rolon – 2025 – Cancer Cytopathology – Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information.
Yahoo
27-05-2025
- Health
- Yahoo
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ -- CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. "We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!" Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. "Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact." For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System - Rivera Rolon - 2025 - Cancer Cytopathology - Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information. View original content to download multimedia: SOURCE CorePlus Servicios Clinicos y Patologicos, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
